WO2018140845A3 - Bi-specific antibodies to cd64 and a disease antigen - Google Patents

Bi-specific antibodies to cd64 and a disease antigen Download PDF

Info

Publication number
WO2018140845A3
WO2018140845A3 PCT/US2018/015651 US2018015651W WO2018140845A3 WO 2018140845 A3 WO2018140845 A3 WO 2018140845A3 US 2018015651 W US2018015651 W US 2018015651W WO 2018140845 A3 WO2018140845 A3 WO 2018140845A3
Authority
WO
WIPO (PCT)
Prior art keywords
mabs
syndrome
antibody
specific antibodies
disease antigen
Prior art date
Application number
PCT/US2018/015651
Other languages
French (fr)
Other versions
WO2018140845A2 (en
Inventor
Patrick C. GEDEON
Anirudh PENUMAKA
John H Sampson
Teilo H. SCHALLER
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of WO2018140845A2 publication Critical patent/WO2018140845A2/en
Publication of WO2018140845A3 publication Critical patent/WO2018140845A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

An antibody-based immunotherapeutic has application for the treatment of GBM and other common neoplasms and diseases. The exquisite epitope-binding-specificity imparted by monoclonal antibodies (mAbs) provides an ideal platform for precisely targeted immunotherapy. Using fully human or humanized mAbs drastically reduces the risk of immunogenicity against the drug and increases clinical safety. Complications associated with murine antibodies previously used in the clinic can be entirely averted. These include cytokine release syndrome24,25 and human anti-mouse antibody (HAMA) formation leading to rapid clearance from patients' serum;26 unpredictable dose-response relationships;23,24 and an acute, potentially severe influenza-like syndrome23,24,27,28.
PCT/US2018/015651 2017-01-27 2018-01-29 Bi-specific antibodies to cd64 and a disease antigen WO2018140845A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762451282P 2017-01-27 2017-01-27
US62/451,282 2017-01-27

Publications (2)

Publication Number Publication Date
WO2018140845A2 WO2018140845A2 (en) 2018-08-02
WO2018140845A3 true WO2018140845A3 (en) 2020-03-26

Family

ID=62979511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/015651 WO2018140845A2 (en) 2017-01-27 2018-01-29 Bi-specific antibodies to cd64 and a disease antigen

Country Status (1)

Country Link
WO (1) WO2018140845A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
CN109694841A (en) * 2019-02-02 2019-04-30 江南大学 A kind of corynebacterium glutamicum recombinant bacterium, preparation method and application
CN117209609B (en) * 2023-11-08 2024-01-30 苏州旭光科星抗体生物科技有限公司 Monoclonal antibody of anti-human CD64 membrane protein and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009186A2 (en) * 1999-07-30 2001-02-08 Medarex, Inc. Therapeutic compounds comprised of anti-fc receptor binding agents
US20110262439A1 (en) * 2008-10-01 2011-10-27 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
US20150071923A1 (en) * 2013-09-12 2015-03-12 Ge Wei Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
US20150132306A1 (en) * 2012-06-07 2015-05-14 Duke University HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
US20150274844A1 (en) * 2009-12-29 2015-10-01 Emergent Product Development Seattle Llc Heterodimer binding proteins and uses thereof
US20160168263A1 (en) * 2013-07-09 2016-06-16 Duke University Certain Improved Human Bispecific EGFRvIII Antibody Engaging Molecules
US20160340439A1 (en) * 2014-01-22 2016-11-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009186A2 (en) * 1999-07-30 2001-02-08 Medarex, Inc. Therapeutic compounds comprised of anti-fc receptor binding agents
US20110262439A1 (en) * 2008-10-01 2011-10-27 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
US20150274844A1 (en) * 2009-12-29 2015-10-01 Emergent Product Development Seattle Llc Heterodimer binding proteins and uses thereof
US20150132306A1 (en) * 2012-06-07 2015-05-14 Duke University HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
US20160168263A1 (en) * 2013-07-09 2016-06-16 Duke University Certain Improved Human Bispecific EGFRvIII Antibody Engaging Molecules
US20150071923A1 (en) * 2013-09-12 2015-03-12 Ge Wei Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
US20160340439A1 (en) * 2014-01-22 2016-11-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHOI, BD: "Antibody-Redirected T- Cell Immunotherapy for Brain Tumors", DISSERTATION, 2013, pages 9, XP055694883 *
DAURKIN, L ET AL.: "Generation of antigen-presenting cells from tumor-infiltrated CD 11b myeloid cells with DNA demethylating agent 5-aza-2-deoxycytidine", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, vol. 59, no. 5, May 2010 (2010-05-01), pages 697 - 706, XP019800191 *
GEDEON, PC ET AL.: "An EGFRvlll-targeted bispecific T- cell engager overcomes limitations of the standard of care for glioblastoma", EXPERT REVIEW OF CLINICAL PHARMACOLOGY, vol. 6, no. 4, July 2013 (2013-07-01), pages 375 - 386, XP055684290 *

Also Published As

Publication number Publication date
WO2018140845A2 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
WO2018140845A3 (en) Bi-specific antibodies to cd64 and a disease antigen
FI3394103T3 (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
CR20160319A (en) ANTIBODY PD-1, FRAGMENT OF UNION TO THE ANTIGEN OF THIS AND MEDICAL USE OF THIS
JP2019502676A5 (en)
FI3932951T3 (en) Methods of treating skin cancer by administering a pd-1 inhibitor
JP2020515247A5 (en)
AR110203A1 (en) ANTI-TIM-3 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES
CA3070790A1 (en) Anti-ctla-4 antibodies and uses thereof
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
PE20161571A1 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
RU2020124153A (en) HUMANIZED HUMAN CD19 ANTIBODIES AND METHODS OF THEIR APPLICATION
AR062840A1 (en) TUMOR THERAPY WITH AN ANTIBODY COMBINATION ANTI RECEIVER OF THE EPIDERMIC GROWTH FACTOR (HER2)
JP2016538318A5 (en)
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
JP2017500028A5 (en)
MX2019014375A (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof.
MX2020007406A (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof.
NZ598670A (en) Antibodies against glucagon receptor and their use
MX2021009041A (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof.
JP2013501058A5 (en)
RU2016107096A (en) MEDICINAL ANTIBODIES CONJUGATES BINDING PROTEINS CD37
RU2016143552A (en) Humanized Antibodies to the Thomsen-Friedenreich Antigen
JPWO2019246514A5 (en)
RU2012108108A (en) CONCENTRATED POLYPEPTIDE MEDICINAL FORMS WITH REDUCED VISCOSITY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18744236

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18744236

Country of ref document: EP

Kind code of ref document: A2